Recently, anti-PD-1 medications, such as pembrolizumab and nivolumab, in combination with chemoradiotherapy or targeted therapy has been reported to effectively inhibit the PD-1/PD-L1 interaction in CRC (10). The gene discussed is PDCD1; the disease is colorectal carcinoma.